Gepotidacin – Oral Products

Minimum Inhibitory Concentrations (mcg/mL) Disk Diffusion (zone diameter in mm) Pathogen S I R S I R Enterobacteralesa, b ≤ 16 32 ≥ 64 ≥ 12 8-11 ≤ 7 Staphylococcus saprophyticusb ≤0.25 - - ≥ 23 - - Enterococcus faecalisb ≤4 - - ≥ 14 - - Neisseria gonorrhoeaec ≤ 1 2 ≥ 4 ≥ 28 23-27 ≤ 22 S = susceptible; I = intermediate; R = resistant a Clinical efficacy was shown for Escherichia coli, Klebsiella pneumoniae, and Citrobacter freundii complex. b Susceptibility interpretive criteria are based on a dose of 1500 mg twice daily. c Susceptibility interpretive criteria are based on a dose of 3000 mg followed by a second dose of 3000 mg approximately 12 hours later.